Lumeon Provides Real-Time Health System Orchestration to Cedars-Sinai Accelerator Powered by Techstars - Gilde Healthcare

Lumeon Provides Real-Time Health System Orchestration to Cedars-Sinai Accelerator Powered by Techstars

23. Oktober 2017

Leading Care Pathway Management Platform to Dynamically Personalize and Streamline Surgery Experience for Patients

BOSTONLumeon, the leader in Care Pathway Management, today announced its participation in the Cedars-Sinai Accelerator Powered by Techstars. Through the Accelerator, Lumeon is collaborating with Cedars-Sinai to identify digital care pathways that can be deployed in care settings throughout the U.S.

Leveraging its experience orchestrating pathways across multiple care specialties through Europe, Lumeon will enable U.S. providers to deliver care in an entirely new way, using intelligent automation. Its unique pathway approach fluidly connects care teams and automated processes, augmenting existing systems with real-time situational awareness.

Within the Accelerator, the company’s initial focus is on surgical pathways, with the aim of reducing cancelations, optimizing length of stay and lowering readmissions – problems that cost the U.S. healthcare industry billions of dollars each year. This approach will enable care teams to deliver a personalized and adaptive care plan for every patient.

“Today, no one has really solved the fundamental issue of care fragmentation, or found a way to deliver end-to-end personalized care at scale, without placing huge strain on resources,” said Lumeon CEO, Robbie Hughes. “The challenge is rarely the care decisions; it’s the difficulty operationalizing them into a longitudinal plan that reliably delivers the best possible care, every time, for every patient.”

“Hospitals around the country understand too well the costs associated with surgical pathways and the impact of same-day cancelations, complications and complex administrative processes,” said Bryan Croft, Senior Vice President Operations, at Cedars-Sinai. “We are excited to have Lumeon in the Accelerator to help explore solutions that can maximize value from our existing technology, and can scale for us across other departments, as well as across other hospitals throughout the U.S.”

“The outstanding surgeons in our system are singularly focused on providing the best possible outcomes for our patients,” said Bruce L. Gewertz, MD, Surgeon-in-Chief and Vice President for Interventional Services at Cedars-Sinai. “One of our key areas of focus is to understand the relationship between task, team, technology and environment. Lumeon has a solution that designs and operationalizes these relationships, adding real value to our patients and care teams.”

Matt Kozlov, Managing Director of the Cedars-Sinai Accelerator Powered by Techstars, added, “We are delighted that Lumeon is part of our 2017 accelerator cohort – we see real potential for the technology to expand across the U.S. hospital and ambulatory market, especially as it’s been built to adapt to each provider’s own care process model.”

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
28. April 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
22. April 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
1. April 2025